TSX VENTURE: HTL
TORONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorne Ltd. (TSX-V: HTL), formerly Calotto Capital Inc., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today reported operational and financial results for the third quarter ended September 30, 2009.
Q3 2009 Highlights - Revenue was $1.46 million compared with $1.43 million in Q3 2008 - Gross profit margin was 66.3 percent compared with 66.1 percent in Q3 2008 - Net loss reduced to $148,000 compared to $283,000 in Q3 2008 - Launched Staccato, an advanced laser system for the automated processing of stem cell colonies to enhance purity and scale-up - Two new peer-reviewed scientific articles published in Nature by customers that reference Hamilton Thorne instruments as part of the research methods - New customers include Weill Cornell Medical Center and an additional lab within theUniversity of California
"With our recent public listing complete, we have embarked on this next stage of our corporate strategy with a focus on sales and marketing of our existing Zilos-tk(R) and XYClone(R) products and generating traction for our recently launched Staccato laser instrument," said Meg Spencer, Chief Executive Officer of Hamilton Thorne Ltd. "While we anticipate our results will continue to reflect the quarter to quarter variability of the business at this stage, we are confident in our long-term prospects as a pre-eminent supplier of the instruments and tools necessary for the exciting field of stem cell research. Staccato is a great example our innovative product offering that targets this growing market. It enhances the scale-up of pure stem cell colonies by providing researchers with an instrument that facilitates the process of separating undesirable stem cells from a colony in scale-up. Our direct
|Copyright©2009 PR Newswire.|
All rights reserved